Copyright
©The Author(s) 2024.
World J Gastroenterol. Jul 21, 2024; 30(27): 3326-3335
Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3326
Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3326
Characteristic | Total patients, n = 195 | ERBL, n = 97 | EFSB, n = 98 | P value |
Male sex | 108 (55.4) | 58 (59.8) | 50 (51.0) | 0.250 |
Age in years | 46.0 (40.0-50.0) | 47.0 (40.5-50.0) | 45.0 (39.5-50.0) | 0.948 |
Goligher classification | ||||
Grade II | 137 (70.3) | 71 (73.2) | 66 (67.3) | 0.231 |
Grade III | 58 (29.7) | 26 (26.8) | 32 (32.7) | |
Haemorrhoid severity score | 8.0 (6.0-9.0) | 9.0 (7.5-10.0) | 8.00 (6.00-9.25) | 0.564 |
Body mass index in kg/m2 | 21.7 (20.0-23.0) | 20.7 (19.0-22.1) | 21.8 (20.0-23.2) | 0.896 |
Haemoglobin in g/L | 130.0 (125.0-138.0) | 129.0 (123.0-139.0) | 134.5 (125.0-138.0) | 0.319 |
Prothrombin time in sec | 12.0 (11.0-12.0) | 12.0 (11.0-12.0) | 11.0 (10.1-12.8) | 0.752 |
Alanine aminotransferase in U/L | 25.0 (16.9-33.0) | 25.0 (15.0-33.0) | 24.0 (19.0-32.3) | 0.316 |
Visual analogue scale | Total patients, n = 195 | ERBL, n = 97 | EFSB, n = 98 | P value |
T11 | ||||
None-mild, ≤ 2 | 103 (52.8) | 39 (40.2) | 64 (65.3) | 0.001 |
Moderate, 3-6 | 90 (46.2) | 56 (57.7) | 34 (34.7) | |
Severe, ≥ 7 | 2 (1.0) | 2 (2.1) | 0 (0) | |
T22 | ||||
None-mild, ≤ 2 | 175 (89.7) | 85 (87.6) | 90 (91.8) | 0.232 |
Moderate, 3-6 | 20 (10.3) | 12 (12.4) | 8 (8.2) | |
Severe, ≥ 7 | 0 (0) | 0 (0) | 0 (0) |
- Citation: Qu CY, Zhang FY, Wang W, Gao FY, Lin WL, Zhang H, Chen GY, Zhang Y, Li MM, Li ZH, Cai MH, Xu LM, Shen F. Endoscopic polidocanol foam sclerobanding for the treatment of grade II-III internal hemorrhoids: A prospective, multi-center, randomized study. World J Gastroenterol 2024; 30(27): 3326-3335
- URL: https://www.wjgnet.com/1007-9327/full/v30/i27/3326.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i27.3326